

cardiotoxicity, and opportunistic infections. **Conclusion:** BTK inhibitors are one of the options for CLL treatment; however, therapy choice should be individualized. Furthermore, potential long-term adverse effects of this drug require monitoring. In future, new combinations of BTK inhibitors with other targeted drugs may expand its role and reduce drug resistance.

<https://doi.org/10.1016/j.htct.2023.09.375>

CHYLOTHORAX AS A MANIFESTATION OF CHRONIC LYMPHOPROLIFERATIVE DISORDER (LPD)

CM Freitas, ACP Silva, NN Kloster, MM Garcia, ERM Neri, ASH Gallotti, AL Tavares, IL Arce, VLP Figueiredo

Hospital do Servidor Público do Estado de São Paulo (HSPE), Instituto de Assistência Médica ao Servidor Público Estadual (IAMSPE), São Paulo, Brazil

Objective: To report the case of a patient diagnosed with Chylothorax secondary to LPD. **Methodology:** Assessment of patient's information kept on HSPE computer-based patient records. Case report: 67-year-old-male with lymphocytosis in peripheral blood in Mar/2016. Complete blood counts: Hb 8.8 g/dL, WBC 38,850/mm³, 92% of lymphocytes (Ly) and no other signs of active disease. Bone marrow flow Cytometry (FC) with 77% of anomalous B Ly (BLy) positive for CD19, CD20, CD22, CD38, CD200, FMC7, IgM and Lambda free light chain (FLC); negative for CD5, CD10, CD11c, CD28, CD103 and Kappa FLC. Matutes score 0. He was diagnosed with LPD and followed up closely. Six months later, he progressed with a history of low-grade fever, weight loss and nocturnal drenching sweats. He was started on Rituximab for 4 cycles in April/2017, followed by 12 cycles (maintenance), achieving disease control. In Feb/22, he got COVID-19 and presented with persistent respiratory symptoms, including dyspnea and dry cough. Thoracic CT scan revealed large right pleural effusion with no thrombosis. Analysis of pleural effusion showed a chylothorax pattern. Abdominal CT scan showed some lymph nodes enlargement (max. 2.3cm). He underwent thoracic drainage due to persistent dyspnea and low oxygen saturation. Pleural fluids built up quickly after drainage. He was submitted to lymphography and embolization of thoracic duct, building up pleural effusion once again a couple of days later. At that time, we considered he had active LPD after pleural effusion FC showed mature BLy positive for CD19, CD20, lambda FLC, CD79b, CD200, CD23, FMC7 and negative for CD5, CD10, CD11c. He was treated with Rituximab, Cyclophosphamide, Vincristine and Prednisone (R-CVP), after which he had complete resolution of the effusion and has been followed up regularly. **Discussion:** Chylothorax is a rare condition caused by the leak of chyle into the pleural cavity. Malignancies are the most common non-traumatic causes of chylothorax, as a result of infiltration of lymphomatous cells or compression by enlarged lymph nodes. It is defined by pleural fluid triglyceride levels >110 mg/dL, presence of chylomicrons, and low cholesterol level. Fifty percent of cases are due to traumas/surgeries while 39% are due to malignancies. Sarcoidosis and Tuberculosis are also possible

causes. Lymphatic anomalies may be involved. As stated by Satriano et al. there are few reports on chylothorax related to COVID19 infection, along with thrombotic events. SARS-CoV2 infection can cause cytokine storms with consequent hyperinflammation and arterial and venous vasculopathy associated with a prothrombotic state. Our patient didn't have any thrombotic event. Currently, there is no general standard therapy for such cases, so the correct approach (drainage, surgeries, drugs/chemotherapy) should be taken in regards to the causative injury. **Conclusion:** this case illustrates well how diverse LPD's manifestations can be. LPD needs to be considered every time a non-traumatic chylothorax appears, especially when there is already a history of malignancies, even though it's a rare condition. Despite his previous COVID-19 diagnosis, our patient didn't present any clear vascular injury which made us find it hard to explain his pleural effusion as secondary to that infection. After having been treated with R-CVP, he's still in disease remission up to this point.

<https://doi.org/10.1016/j.htct.2023.09.376>

PACIENTES COM LEUCEMIA LINFOCÍTICA CRÔNICA EXPOSTOS À COVID-19, EM USO DE RITUXIMAB E INIBIDORES DE TIROSINA QUINASE DE BRUTON

LB Moraes, LT Carvalho, GRR Neto, NFN Mello, DE Baima, AP Praxedes, GK Nobrega, LLM Perobelli

Universidade Anhembi Morumbi, São Paulo, SP, Brasil

Esta revisão apresenta uma visão geral de como a COVID-19 influencia o prognóstico de pacientes com leucemia linfocítica crônica (LLC) tratados com rituximab ou inibidores da tirosina quinase de Bruton (BTKi), com ou sem quimioterapia. A seleção do material foi baseada em estudos prévios que examinaram as taxas de morbidade e mortalidade associadas à infecção por SARS-CoV-2 em pacientes com LLC submetidos a esses tratamentos. O objetivo deste texto é mostrar como a pandemia do COVID-19 afetou a evolução dos pacientes com LLC, os quais utilizam BTKi ou Rituximab. Sua metodologia empregou as bases de dados do PubMed e da Cochrane Library, com seleção criteriosa e estratégia de busca que abrangeu de forma adequada todos os artigos relevantes, em relação ao tema. As palavras-chaves e estratégia utilizada são: ("Chronic lymphocytic leukemia" OR CLL) AND (SARS-CoV-2 OR COVID-19) AND (Rituximab OR Treatment OR "Anti-CD20 blocker" OR "BTK inhibitor"). Com os dados mais pertinentes dos estudos obtidos, foram montados os resultados e a discussão, assim reforçando a tese abaixo. Os indivíduos com LLC que usam rituximab apresentam um prognóstico pior por possuírem maior probabilidade de desenvolver uma forma mais grave da COVID-19. Por outro lado, os BTKi demonstraram apresentar uma possível redução na morbidade dos mesmos. Portanto, é necessário uma análise criteriosa na prescrição desses medicamentos aos pacientes com LLC.

<https://doi.org/10.1016/j.htct.2023.09.377>